Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants.
暂无分享,去创建一个
J. Garber | N. Tung | H. Rana | J. Weitzel | D. Castillo | Alison Schwartz | Sophie Hyman | S. Stokes
[1] Joshua L. Deignan,et al. Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.
[2] B. Karlan,et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] N. Tung,et al. Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome , 2020 .
[4] K. Postula,et al. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood-Limited in Patients Undergoing Hereditary Cancer Panel Testing. , 2019, The Journal of molecular diagnostics : JMD.
[5] S. Manley,et al. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next‐generation sequencing hereditary pan‐cancer panel are acquired somatically , 2019, Human mutation.
[6] J. Garber,et al. Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis , 2019, Breast Cancer Research.
[7] S. Neuhausen,et al. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. , 2019, Cancer genetics.
[8] R. Gelman,et al. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing , 2018, Journal of the National Cancer Institute.
[9] K. Shaw,et al. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell‐free DNA by next‐generation sequencing , 2018, Cancer.
[10] C. Gau,et al. Somatic TP53 variants frequently confound germline testing results , 2017, Genetics in Medicine.
[11] L. Guerrini-Rousseau,et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome , 2017, Journal of Medical Genetics.
[12] M. Ladanyi,et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. , 2017, Cell stem cell.
[13] S. Manley,et al. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. , 2017, Cancer genetics.
[14] C. Bonaïti‐pellié,et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[16] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[17] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[18] M. Stratton,et al. A Pathogenic Mosaic TP53 Mutation in Two Germ Layers Detected by Next Generation Sequencing , 2014, PloS one.
[19] H. Meijers-Heijboer,et al. TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes , 2010, Journal of Medical Genetics.
[20] Catherine Bonaïti-Pellié,et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Malkin,et al. High frequency of de novo mutations in Li–Fraumeni syndrome , 2009, Journal of Medical Genetics.
[22] S. Sommer,et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Z. Sedlacek,et al. Somatic TP53 mutation mosaicism in a patient with Li–Fraumeni syndrome , 2009, American journal of medical genetics. Part A.
[24] E. Pinto,et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. , 2004, Arquivos brasileiros de endocrinologia e metabologia.
[25] R. Eeles,et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.
[26] J. Fraumeni,et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[27] J. Fraumeni,et al. Multiple primary cancers in families with Li-Fraumeni syndrome. , 1998, Journal of the National Cancer Institute.
[28] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[29] W. Blattner,et al. A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.
[30] J. Fraumeni,et al. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.